Exactly this.
And the goalpost that they will have a positive cash flow by 2020 is even more laughable than last year's claim of sales by Q4 2017. Management need to stop BSing shareholders.
Expect more credit raises to keep things afloat until a professional biotech buys the IP and makes the dream a reality.
Ann: $7m Oversubscribed Private Placement & Launch of $1m SPP, page-35
-
- There are more pages in this discussion • 95 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add LBT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.002(11.8%) |
Mkt cap ! $23.31M | |||
| Open | High | Low | Value | Volume |
| 1.6¢ | 1.6¢ | 1.4¢ | $66.59K | 4.467M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 486857 | 1.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.5¢ | 702681 | 1 |
View Market Depth
| Last trade - 15.53pm 28/06/2024 (20 minute delay) ? |
| LBT (ASX) Chart |